Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase
about
PTPN14 is required for the density-dependent control of YAP1Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the 'PTP-ome'Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsPtpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesisThe fate of chemoresistance in triple negative breast cancer (TNBC)The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodesTemporal regulation of EGF signalling networks by the scaffold protein Shc1miR-1279, miR-548j, miR-548m, and miR-548d-5p binding sites in CDSs of paralogous and orthologous PTPN12, MSH6, and ZEB1 GenesMST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer.Regulation of the Src kinase-associated phosphoprotein 55 homologue by the protein tyrosine phosphatase PTP-PEST in the control of cell motilityProtein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis.Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.A New Bliss Independence Model to Analyze Drug Combination Data.BIMMER: a novel algorithm for detecting differential DNA methylation regions from MBDCap-seq data.PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity.Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes.ER-alpha-cDNA as part of a bicistronic transcript gives rise to high frequency, long term, receptor expressing cell clones.Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.REST controls self-renewal and tumorigenic competence of human glioblastoma cells.Quantification of the host response proteome after mammalian reovirus T1L infection.A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokersA loss-of-function screen for phosphatases that regulate neurite outgrowth identifies PTPN12 as a negative regulator of TrkB tyrosine phosphorylation.Metformin and erlotinib synergize to inhibit basal breast cancer.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Triple-negative and basal-like breast cancer: implications for oncologists.Protein tyrosine phosphatase-PEST and β8 integrin regulate spatiotemporal patterns of RhoGDI1 activation in migrating cellsAn ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K SignalingACAP4 protein cooperates with Grb2 protein to orchestrate epidermal growth factor-stimulated integrin β1 recycling in cell migrationElevated PI3K signaling drives multiple breast cancer subtypes.Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1.Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cellsA targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.The prognostic significance of tyrosine-protein phosphatase nonreceptor type 12 expression in nasopharyngeal carcinoma.Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility
P2860
Q24297998-CCCCCBA6-6BA1-4DC6-A544-F1BCE7F84082Q24309666-462AE235-C57C-4E1A-9B28-20E22A6DC834Q24339394-97AC76D8-98CA-4416-A6C5-4981E6E1A5A8Q24632905-2F24FF8D-1D11-4FC9-A886-B4597CD77CA4Q26775232-868326DD-69CE-45C6-B782-46BFF74AEB25Q28118816-7059D358-9726-4C68-91AA-A4E86BE72C9DQ28294401-65026DCE-E65A-4AA7-AC44-292AC7A324D3Q28690612-87F50B31-71A8-4263-B7DA-9B19E8C078A8Q30009013-320183A5-A14F-4D7A-A15E-E7EB724A7383Q30009597-74D272E6-1C4E-4430-AFBD-FD26F542A7BFQ30009828-1F6B62CA-F3C4-4CA6-A2FA-8E10BB7EDD72Q30368024-20878D02-1BA3-4BD0-9B64-BEE8D955F970Q30582030-527FD7F2-8165-451D-9673-552E6F923E82Q30747693-5C1367B3-C356-4DED-9430-405700CA0B46Q30874301-3FA9B6E7-6427-4A1B-901E-4CE109E80042Q33557675-310F11E2-BDF0-4BF5-BC56-1530EE0093D0Q33612132-0FC3476D-1E4D-40FF-AA30-524579A0690CQ33874621-4530ABFE-C341-4A32-8E85-8746EDF25160Q34171530-EEFA84B4-83AF-4D17-933A-C9972FED8F15Q34274373-24F386D9-6989-44E3-A681-F10E551BD71EQ34305458-8A09AE5F-630D-40C3-9882-C5FD6B426E0BQ34512626-DD7E18AC-A1D0-481A-B25A-CF655816EFA4Q34584344-DFDF4724-E06D-4864-903F-4C51D351E574Q34778691-E25E9AFF-615B-481B-BC5E-AB0C507B5407Q34786488-8F0FF8D4-4E4B-4508-9B10-81FFE46396A5Q34978420-DF0C48CF-2A86-4996-850A-F75FBF301DCBQ35077627-A1695B38-17CC-4730-8FF2-28703FE88534Q35145642-BDED5B26-2B9D-4EC3-8F30-97C54BCDB59CQ35214716-6AE3BBCF-C2EE-479D-8F72-9571C953A1CCQ35593321-63E35AD6-8371-4412-A19F-A4141A90FD87Q35626201-B9E6A875-515A-4BCF-B4ED-8D2A2BAFA307Q35640263-0CC206A3-611F-4DE8-BF41-06A070E4863DQ35749654-9F6BE098-37B1-4A05-A255-8C74BAC38C67Q35793909-D106875E-4D8F-4628-9566-94EF0EEE03C3Q35832242-2A758902-AB0C-4344-B86A-E26D669222A7Q35879903-0C244FF9-534E-4454-818C-AEA3EAB4D614Q35886083-68F617A1-23BD-49A8-8BEF-A0841EF93AD2Q35894633-BA629F19-F538-4928-BAD7-BE8A611850B5Q35895370-89D3C3BF-5672-4E85-ABD3-6DA9D70969C4Q35930790-B4120BBA-36B4-4E0D-86DE-F7364A5CBB47
P2860
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@ast
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en-gb
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@nl
type
label
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@ast
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en-gb
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@nl
prefLabel
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@ast
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en-gb
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@nl
P2093
P2860
P50
P3181
P1433
P1476
Activation of multiple proto-o ...... loss of the PTPN12 phosphatase
@en
P2093
C Kent Osborne
Chad J Creighton
Chunshui Zhou
David A Wheeler
Don X Nguyen
Donna Muzny
Earlene Schmitt
Ilenia Migliaccio
Jessica D Kessler
P2860
P304
P3181
P356
10.1016/J.CELL.2011.02.003
P407
P577
2011-03-01T00:00:00Z